Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

Conditions: Diabetes
Interventions: Drug: metforminpioglitazoneexenatide; Drug: metformin, glyburide and glargine
Sponsors: The University of Texas Health Science Center at San Antonio; American Diabetes Association; Amylin Pharmaceuticals, LLC.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 24, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments